1 reports of this reaction
50.0% of all ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR reports
#1 most reported adverse reaction
COVID 19 is the #1 most commonly reported adverse reaction for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, manufactured by Haleon US Holdings LLC. There are 1 FDA adverse event reports linking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR to COVID 19. This represents approximately 50.0% of all 2 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 is a frequently reported adverse event for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, accounting for a significant proportion of all reports.
In addition to covid 19, the following adverse reactions have been reported for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR:
The following drugs have also been linked to covid 19 in FDA adverse event reports:
COVID 19 has been reported as an adverse event in 1 FDA reports for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 accounts for approximately 50.0% of all adverse event reports for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, making it one of the most commonly reported side effect.
If you experience covid 19 while taking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.